Fluconazole is an antifungal agent of the triazole class, a potent selective inhibitor of the fungal enzymes needed for ergosterol synthesis. The primary mechanism of its action is the inhibition of fungal lanosterol 14α-demethylation mediated by cytochrome P450, which is an integral stage of fungal ergosterol biosynthesis.
In adults, for the treatment of:
– cryptococcal meningitis;
– invasive candidiasis;
– mucosal candidiases including candidiasis of the oropharynx and oesophagus, candiduria, chronic candidiasis of the skin and mucosa;
– chronic atrophic candidiasis (candidiasis caused by the use of dentures) if local therapy is ineffective.
In adults, for the prevention of:
– relapse of cryptococcal meningitis in patients with a high risk of its development;
– relapse of candidiasis of the oropharynx and oesophagus in patients with HIV with a high risk of its development;
– prevention of candidal infections in patients with prolonged neutropenia (e.g. in patients with blood malignancies receiving chemotherapy, or in patients with haematopoietic stem cell transplantation).
The dose of fluconazole depends on the type and severity of the fungal infection.
If repeated use of the drug is needed, the treatment of the infections should be continued until the disappearance of clinical and laboratory signs of the fungal activity. Insufficient treatment duration can lead to reemergence of an active infectious process.
The drug is administered intravenously by infusion. There is no need to change the daily dose when changing the route of administration from oral to intravenous and vice versa.